If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-15. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Zapomeran, sold under the brand name Kostaive is a self-amplifying mRNA-based COVID-19 vaccine. It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein. Self-amplifying means that the mRNA also carries instructions to make a protein called replicase. It was developed under the name ARCT-154, also known as VBC-COV19-154 in Vietnam, by Arcturus Therapeutics. For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing. Zapomeran was approved for medical use in Japan in November 2023, and it is the first self-amplifying mRNA-based COVID-19 vaccine to be approved. Zapomeran was authorized for medical use in the European Union in February 2025, and in the UK in January 2026.
=== Agents of spontaneous missense mutation === Environmental mutagens, such as tobacco smoke or UV radiation, may be a cause of spontaneous missense mutations. Tobacco smoke has been implicated in transversion mutations in the K-ras gene, with a meta-analysis of lung carcinomas showing 25 tumours containing a G to T mutation causing an amino acid change from glycine to cysteine, and 11 tumours with a G to T mutation causing an amino acid change from glycine to valine. Similarly, numerous studies have shown ultraviolet light induces missense mutations in the p53 gene, which when unregulated, reduces the cell's ability to recognize DNA damage and engage in apoptosis, leading to cell proliferation and potential skin carcinogenesis.
Jan van Helmont began the research of the process in the mid-17th century when he carefully measured the mass of the soil a plant was using and the mass of the plant as it grew. After noticing that the soil mass changed very little, he hypothesized that the mass of the growing plant must come from the water, the only substance he added to the potted plant. His hypothesis was partially accurate – much of the gained mass comes from carbon dioxide as well as water. However, this was a signaling point to the idea that the bulk of a plant's biomass comes from the inputs of photosynthesis, not the soil itself. Joseph Priestley, a chemist and minister, discovered that when he isolated a volume of air under an inverted jar and burned a candle in it (which gave off CO2), the candle would burn out very quickly, much before it ran out of wax. He further discovered that a mouse could similarly "injure" air. He then showed that a plant could restore the air the candle and the mouse had "injured". In 1779, Jan Ingenhousz repeated Priestley's experiments. He discovered that it was the influence of sunlight on the plant that could cause it to revive a mouse in a matter of hours. In 1796, Jean Senebier, a Swiss pastor, botanist, and naturalist, demonstrated that green plants consume carbon dioxide and release oxygen under the influence of light. Soon afterward, Nicolas-Théodore de Saussure showed that the increase in mass of the plant as it grows could not be due only to uptake of CO2 but also to the incorporation of water.
Grifols began in 1909 when hematologist and scientist Josep Antoni Grífols i Roig founded a clinical analysis laboratory in Barcelona: the Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos, a precursor to Laboratorios Grifols. In Spain, Grífols i Roig patented the first instrument for carrying out indirect blood transfusions, the transfusion flebula. Post-war, Grífols i Roig and his sons, Josep Antoni Grífols i Lucas, a hematologist, and Víctor Grífols i Lucas, a chemist and pharmacist, founded Laboratorios Grifols, which began the start of the business dedicated to clinical analysis and the preparation of freeze-dried plasma. In 1952, for the first time, the results of a systematic application of the plasmapheresis technique in humans was published in the British Medical Journal thanks to a study led by Josep Antoni Grífols i Lucas. Control of the company was handed down to Víctor Grifols Roura in 1987, when Grifols created the holding company Grupo Grifols. This unified the commercial company with its clinical diagnostic, plasma-derived medicines and parenteral operations. From there, in 1988 Grifols opened its first subsidiary, in Portugal, marking the beginning of the company’s international expansion.
== Effects == The down side of this method is that it is difficult to achieve as good results of glycemic control as with intensive insulin therapy. The advantage is that, for diabetics with a regular lifestyle, the regime is less intrusive than the intensive therapy.
Sources: en.wikipedia.org
Although most yeasts have only a single actin gene, higher eukaryotes, in general, express several isoforms of actin encoded by a family of related genes. Mammals have at least six actin isoforms coded by separate genes, which are divided into three classes – alpha, beta, and gamma – according to their isoelectric points. In general, alpha actins are found in muscle (α-skeletal, α-aortic smooth, α-cardiac), whereas beta and gamma isoforms are prominent in non-muscle cells (β-cytoplasmic, γ1-cytoplasmic, γ2-enteric smooth). Although the amino acid sequences and in vitro properties of the isoforms are highly similar, these isoforms cannot completely substitute for one another in vivo. Plants contains more than 60 actin genes and pseudogenes. The typical actin gene has an approximately 100-nucleotide 5' UTR, a 1200-nucleotide translated region, and a 200-nucleotide 3' UTR. The majority of actin genes are interrupted by introns, with up to six introns in any of 19 well-characterised locations. The high conservation of the family makes actin the favoured model for studies comparing the introns-early and introns-late models of intron evolution.
Several Latin American and Caribbean countries have, at times, faced allegation governments involvement in the illegal drug trade the 1970s and 1980s.In 1978 and 1980, so called "cocaine coups" in Honduras and Bolivia brought such governments to power that were linked to drug trafficking networks (see illegal drug trade in Honduras and illegal drug trade in Bolivia). In Panama, Manuel Noriega, a long-term drug trafficker, served as a head of military from 1983 to 1989, during which he maintained ties with the CIA. The Colombian parapolitics scandal revealed links between parts of the Colombian establishment and the United Self-Defense Forces of Colombia (AUC), a paramilitary group responsible for killing tens of thousands of Colombian civilians, which controls over 75% of the Colombian cocaine trade. The illegal drug trade in Peru was until 2000 shaped by Vladimiro Montesinos's involvement; he had been head of the country's intelligence service since 1990. In 2010 it was alleged that the Mexican Sinaloa cartel had used bribery to co-opt the federal government and focus the government's anti-drug efforts on its competitors. According to Peter Dale Scott, "The Guadalajara Cartel, Mexico's most powerful drug-trafficking network in the early 1980s, prospered largely because it enjoyed the protection of the DFS, under its chief Miguel Nazar Haro, a CIA asset." Now, in the 21st century, there are still major issues with government corruption in Latin America.
The Dynamin-related protein 2b/drp2b gene in A. thaliana is not directly an immunity gene, but by helping move external material into the intracellular network is indirectly related, and some mutants increase susceptibility.
During an interview with The Times in December 2021, Collins announced that the pair were planning to get re-engaged however were waiting for the completion of Hawash's divorce to his previous wife, whom Collins has a good relationship with and acts as stepmother to their son. Collins also discussed her plans to have a baby with Hawash as well as a television show to document the pregnancy and baby's birth. In February 2024, Collins and Hawash became engaged for the second time after he proposed to her on a beach during their holiday in the Maldives.
Sources: en.wikipedia.org
According to the White House's website, whitehouse.gov, more than 200 organizations have stated their support for the OBBBA, including AT&T, Comcast, American Airlines, Delta Air Lines, the National Retail Federation, and the National Taxpayers Union. Trump has claimed that the bill is the "single most popular bill ever signed", a claim that CNN disputed, saying "That is an up-is-down reversal of reality. ... While polls can be off, this bill wouldn't be popular – let alone the most popular US bill ever signed – even with a massive and widespread polling error."
Concurrently, the Bureau of Longitude Studies and the Observatory were undertaking a comprehensive review of his extensive barometric and astronomical measurements. Furthermore, artists had been commissioned to commence the replication of his botanical sketches and illustrations of ancient Indian monuments. At this time, Napoleon Bonaparte was the only person in Europe with greater fame than Humboldt. Their sole meeting was unsuccessful, with Napoleon responding coldly, possibly viewing Humboldt as a politically suspect foreigner. Despite this, Napoleon granted a pension to Bonpland but later attempted to expel Humboldt from Paris on suspicion of espionage. Paris, despite political changes since Humboldt’s departure, was now the leading center of science, offering exceptional resources and collaborators. Humboldt chose to remain, preferring Paris’s intellectual and social environment over Berlin, which he considered unappealing. He immersed himself in work, organizing his extensive collections and distributing specimens to various institutions. Bonpland kept the most complete set of plant specimens, with other collections sent to major European botanical gardens. Humboldt’s dedication to processing and publishing his scientific findings required several years of intense effort. During their American expedition, Alexander von Humboldt and Aimé Bonpland encountered numerous challenges and hardships, many of which were described in Humboldt’s Voyage aux régions équinoxiales du Nouveau Continent and related works.
=== Glutamate transport === Citicoline lowers increased glutamate concentrations and raises decreased ATP concentrations induced by ischemia. Citicoline also increases glutamate uptake by increasing expression of EAAT2, a glutamate transporter, in vitro in rat astrocytes. It is suggested that the neuroprotective effects of citicoline after a stroke are due in part to citicoline's ability to decrease levels of glutamate in the brain. This is in part due to an indirect decrease in the extrasynaptic NMDA-TRMP4 death signaling pathway. It's important to also note it is only the extrasynaptic NMDA receptors responsible for excitotoxicity.
=== Quigley Company asbestos settlement (2013) === The Quigley Company, which sold asbestos-containing insulation products until the early 1970s, was acquired by Pfizer in 1968. In June 2013, asbestos victims and Pfizer negotiated a settlement that required Pfizer to pay a total of $964 million: $430 million to 80% of existing plaintiffs and place an additional $535 million into a settlement trust that will compensate future plaintiffs as well as the remaining 20% of plaintiffs with claims against Pfizer and Quigley. Of that $535 million, $405 million is in a 40-year note from Pfizer, while $100 million is from insurance policies.
== First published posthumously == De Profundis (written 1895–97, in Reading Gaol). Expurgated edition published 1905; suppressed portions 1913, expanded version in The Letters of Oscar Wilde (1962). The Rise of Historical Criticism (written while at college). First published in 1905 (Sherwood Press, Hartford, CT), privately printed. Reprinted in Miscellanies, the last volume of the First Collected Edition (1908). The First Collected Edition (Methuen & Co., 14 volumes) appeared in 1908 and contained many previously unpublished works. The Second Collected Edition (Methuen & Co., 12 volumes) appeared in installments between 1909–11 and contained several other unpublished works. The Letters of Oscar Wilde (written 1868–1900). Published in 1962. Republished as The Complete Letters of Oscar Wilde (2000), with letters discovered since 1962 and new annotations by Merlin Holland. The Women of Homer (written 1876, while at college). First published in Oscar Wilde: The Women of Homer (2008) by the Oscar Wilde Society.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.